Kymera Therapeutics in Boston is seeking a strategic leader for the commercialization of KT-621, a novel protein degrader for immune-mediated diseases. This role involves shaping the global commercial strategy and ensuring successful launch readiness.
The ideal candidate should possess 15+ years in pharmaceutical or biotechnology, particularly with immunological products. Kymera offers a competitive compensation range of $315,000 – $395,000 along with bonuses and equity participation.
#J-18808-LjbffrGlobal Commercial Lead, Immunology & KT-621 Launch in boston at Unknown Company
This position is listed as full time and onsite.